CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that, effective immediately, it will begin operating as BIND Therapeutics to reflect the Company’s progress in applying its Medicinal Nanoengineering® platform to develop a pipeline of highly selective targeted and programmable therapeutics called Accurins. Simultaneous with the name change, the company has launched a new corporate website and URL ‘www.BINDTHERAPEUTICS.COM’
